期刊文献+

免疫毒性评价方法研究进展 被引量:1

原文传递
导出
摘要 近年来,随着外源化学物对机体免疫功能的影响越来越受到关注,免疫毒性评价方法也在不断发展。在国内外相关机构和组织对免疫毒性体内评价方法进行规范和标准化的同时,体外检测模型的构建和相关方法的发展以及基因组学在免疫毒性评价方面的应用等也已成为新的研究热点。本文仅就免疫毒性评价方法及其体外检测方法的发展、毒理基因组学的应用以及发育免疫毒性评价方法的发展作一简要综述,为免疫毒性评价方法的选择和实际应用提供参考。
出处 《卫生研究》 CAS CSCD 北大核心 2013年第5期880-884,共5页 Journal of Hygiene Research
基金 "863"计划重大项目(No.2010AA023001) 国家自然科学基金重点项目(No.81030053)
  • 相关文献

参考文献26

  • 1LUEBKE R. Immunotoxicity screening and prioritization in the twenty-first century[J]. Toxicol Pathol, 2012, 40(2): 294-299.
  • 2ICH. Guidance for industry: S8 immunotoxicity studies for human pharmaceuticals[S]. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006.
  • 3Regulation (EC) No 1907 12006 of The European Parliament and of The Council of 18 December 2006: Concerning the Registration, Evaluation, Autho?risation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/451EC and repealing Council Regulation (EEC) No 793193 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/1551EEC, 93/67/EEC, 93/1051EC and 20001 2l1EC[S]. OfficialJournal of the European Union, 2006.
  • 4GENNARI A, BAN M, BRAUN A, et a1. The use of in vitro systems for evaluating immunotoxicity , The report and recommendations of an ECV AM workshop[J].J Immunotoxicol, 2005, 2: 61-83.
  • 5VAN DER LAANJ W , VAN LOVEREN H. Current status and burning issues in immunotoxicity testing of drugs[J]. Toxicol Appl Pharm , 2005, 207: 5435-5440.
  • 6CARFI M, GENNARI A, MALERBA I, et al. In vitro tests to evaluate immunotoxicity , a preliminary study[J]. Toxicology, 2007 , 229: 11-22.
  • 7DURAMAD P, HOLLAND N T. Biomarkers of immunotoxicity for environmental and public health research[J]. IntJ Environ Res Public Health, 2011,8: 1388-1401.
  • 8ULLERAS E, TRZASKA D, ARKUSZJ, et al. Development of the "Cell Chip": a new in vitro alternative technique for immunotoxicity testing[J]. Toxicology, 2005, 206: 245-256.
  • 9BURNS-NAAS LA, KERKVLIET N I, LASKIN D L, et a1. The use of multiparameter flow cytometry in immunotoxicology and immunopharmacology[M] II LUEBKE R W, HOUSE R, KIMBER I, Eds. Immunotoxicology and Immunopharmacology. 3rd ed. Boca Raton: CRC Press, 2007: 97-122.
  • 10TOMAR N, DE R K. Immunoinformatics , An integrated scenario[J]. Immunology, 2010, 131: 153-168.

同被引文献7

  • 1WHO. Breast cancer: prevention and control [ EB/OL ]. [ 2015 - 08 -24]. http://www, who. int/cancer/detection/breastcancer/en/indexl, html.
  • 2HUANG Y, FU P, FAN W. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer[ J ]. Curr Drug Targets, 2013,14 ( 8 ) : 889 - 898.
  • 3SOLIMAN H. Immunotherapy strategies in the treatment of breast cancer[ J ]. Cancer Control, 2013, 20 ( 1 ) : 17 - 21.
  • 4MAVROUDIS D, SALOUSTROS E, MALAMOS N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) [ J]. Ann Oncol, 2015, 26 (7): 1333 - 1340.
  • 5SWAIN SM, BASELGA J, KIM SB, et al. Pertuzumab, trastu- zumab, and docetaxel in HER2-positive metastatic breast cancer [Jl. NEnglJMed, 2015,372(8):724-734.
  • 6FDA. Highlights of prescribing information [ EB/OL]. [2015 - 08 -24 ]. http://www, accessdata, fda. gov/drugsatfda_docs/la- bel/2013/125409 s051 lbl. pdf.
  • 7周晓冰,李正东,孙立,齐卫红,杨艳伟,王秀文,梁瑞安,李波.食蟹猴静脉注射抗CD20功能人源化单克隆抗体SM09重复给药毒性研究[J].中国新药杂志,2012,21(6):616-622. 被引量:5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部